AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35130256 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 100
Study 36400157 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft and gingival free graft
Number of subjects: 40
Study 36400157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense polytetrafluoroethylene membrane
Number of subjects: 40
Study 36400157 — intervention group
Group type: COMPARATOR
Intervention: Natural socket healing (blood clot)
Number of subjects: 40
Study 36400157 — intervention group
Group type: COMPARATOR
Intervention: Platelet rich fibrin plugs
Number of subjects: 40
Study 33634747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with movement (MWM)
Number of subjects: 51
Study 33634747 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 51
Study 32456456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention effect assessment using block randomization
Number of subjects: 0
Study 32456456 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection of single-case data
Number of subjects: 0
Study 32456456 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical representations for consistency assessment
Number of subjects: 0
Study 32086359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume high-intensity interval training (HIT)
Number of subjects: 64
Study 32086359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIT)
Number of subjects: 64
Study 32086359 — intervention group
Group type: COMPARATOR
Intervention: Control group with no exercise
Number of subjects: 64
Study 32086359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume HIT, Low-volume HIT, Control group
Number of subjects: 64
Study 34089969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (calcifediol)
Number of subjects: 0
Study 34089969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32164597 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention
Number of subjects: 27
Study 35511204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cottonseed oil (CSO)
Number of subjects: 43
Study 33722838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 pmol GLP‐1/kg/min
Number of subjects: 29
Study 33722838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 pmol GLP‐1/kg/min
Number of subjects: 29
Study 33722838 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 pmol GLP‐1/kg/min
Number of subjects: 29
Study 33722838 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study 33722838 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 infusions
Number of subjects: 29
Study 33176812 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninsured URAS
Number of subjects: 181
Study 33176812 — intervention group
Group type: COMPARATOR
Intervention: Thai population
Number of subjects: 181
Study 35232315 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel shoes
Number of subjects: 18
Study 35232315 — intervention group
Group type: COMPARATOR
Intervention: Usual shoes
Number of subjects: 18
Study 33740382 — intervention group
Group type: EXPERIMENTAL
Intervention: novel SnF2 dentifrice containing the amino acid glycine
Number of subjects: 100
Study 33740382 — intervention group
Group type: COMPARATOR
Intervention: negative control sodium monofluorophosphate dentifrice
Number of subjects: 100
Study 35931879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg at weeks 0, 4, 8, 12, and 16 (arm 1)
Number of subjects: 185
Study 35931879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg at weeks 0, 4, and 16 (arm 2)
Number of subjects: 185
Study 35931879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg at weeks 0 and 12 (arm 3)
Number of subjects: 185
Study 35931879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 75 mg at week 0 (arm 4)
Number of subjects: 185
Study 35931879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arm 5)
Number of subjects: 185
Study 35931879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (all arms)
Number of subjects: 185
Study 35931879 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg
Number of subjects: 185
Study 32168992 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice of copying a novel movement
Number of subjects: 0
Study 32168992 — intervention group
Group type: COMPARATOR
Intervention: Non-autistic people
Number of subjects: 0
Study 36097029 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous mRNA vaccination (third dose of the same mRNA)
Number of subjects: 46
Study 36097029 — intervention group
Group type: COMPARATOR
Intervention: Heterologous vector vaccination (ChAdOx1 nCoV‐19)
Number of subjects: 46
Study 36097029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vector and mRNA vaccines (third dose)
Number of subjects: 46
Study 33738704 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% melatonin oral gel
Number of subjects: 84
Study 33738704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 32056812 — intervention group
Group type: EXPERIMENTAL
Intervention: SSE + KT
Number of subjects: 36
Study 32056812 — intervention group
Group type: COMPARATOR
Intervention: SSE
Number of subjects: 36
Study 36287585 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Sensitive Educational Video (CSEV)
Number of subjects: 1564
Study 36287585 — intervention group
Group type: COMPARATOR
Intervention: Current information brochure
Number of subjects: 1564
Study 34062603 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-frequency pure-tone screener (FFS)
Number of subjects: 1665
Study 34062603 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method for testing of auditory sensitivity (AMTAS)
Number of subjects: 1665
Study 34062603 — intervention group
Group type: EXPERIMENTAL
Intervention: Digits-in-noise test (DIN)
Number of subjects: 1665
Study 34062603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hearing screening)
Number of subjects: 1665
Study 32781849 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw and staple-plate (2 screws and an 18-mm nitinol staple)
Number of subjects: 20
Study 32781849 — intervention group
Group type: COMPARATOR
Intervention: Single 5.5-mm cannulated screw
Number of subjects: 20
Study 36090631 — intervention group
Group type: EXPERIMENTAL
Intervention: Claw-suture localization device
Number of subjects: 411
Study 36090631 — intervention group
Group type: COMPARATOR
Intervention: Hookwire localization device
Number of subjects: 411
Study 36090631 — intervention group
Group type: EXPERIMENTAL
Intervention: Claw-suture localization device (multiple localization subgroup)
Number of subjects: 411
Study 32690074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with budesonide (1mg/2mL diluted in 250mL of physiological saline 9°/00) for 30 days, along with olfactory rehabilitation twice a day.
Number of subjects: 120
Study 32690074 — intervention group
Group type: COMPARATOR
Intervention: Nasal irrigation with physiological saline 9°/00 only for 30 days, along with olfactory rehabilitation twice a day.
Number of subjects: 120
Study 34555031 — intervention group
Group type: EXPERIMENTAL
Intervention: HD204
Number of subjects: 119
Study 34555031 — intervention group
Group type: COMPARATOR
Intervention: EU-sourced bevacizumab
Number of subjects: 119
Study 34555031 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 119
Study 36194987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitspiration TikTok videos
Number of subjects: 120
Study 36194987 — intervention group
Group type: COMPARATOR
Intervention: Art control TikTok videos
Number of subjects: 120
Study 33507712 — intervention group
Group type: EXPERIMENTAL
Intervention: enterade®
Number of subjects: 114
Study 33507712 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 114
Study 35709234 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left DLPFC
Number of subjects: 18
Study 35709234 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS over the left DLPFC
Number of subjects: 18
Study 35709234 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS over the left DLPFC
Number of subjects: 18
Study 34324433 — intervention group
Group type: EXPERIMENTAL
Intervention: MR‐proADM
Number of subjects: 126
Study 34324433 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 126
Study 32185856 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen membrane with 1:1 autogenous and anorganic bovine bone mineral (ABBM) mixture
Number of subjects: 20
Study 32185856 — intervention group
Group type: COMPARATOR
Intervention: Titanium mesh with 1:1 autogenous and anorganic bovine bone mineral (ABBM) mixture
Number of subjects: 20
Study 33556290 — intervention group
Group type: EXPERIMENTAL
Intervention: ReDO-10 programme
Number of subjects: 21
Study 33287597 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation intervention provided by municipal social workers (n=83)
Number of subjects: 347
Study 33287597 — intervention group
Group type: COMPARATOR
Intervention: Usual municipal RTW management (n=264)
Number of subjects: 347
Study 33287597 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation intervention for participants with breast cancer (n=290)
Number of subjects: 347
Study 32003278 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine with epinephrine (group B)
Number of subjects: 60
Study 32003278 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (group R)
Number of subjects: 60
Study 32003278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of 0.5% bupivacaine with epinephrine and 2% lignocaine (group BL)
Number of subjects: 60
Study 33938371 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐(Methylsulfinyl)hexyl isothiocyanate (6‐MSITC) 9 mg/day
Number of subjects: 8
Study 33938371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 34279726 — intervention group
Group type: EXPERIMENTAL
Intervention: IV metoprolol
Number of subjects: 270
Study 33966396 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation exercises for 6 months
Number of subjects: 93
Study 33966396 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing and rehabilitation training
Number of subjects: 93
Study 33333734 — intervention group
Group type: EXPERIMENTAL
Intervention: INSIGHTS intervention
Number of subjects: 127
Study 33333734 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 127
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× feeding frequency (0700, 1600, and 2200 h)
Number of subjects: 48
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.76 kg of solid per day (high feeding rate)
Number of subjects: 48
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× feeding frequency
Number of subjects: 48
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 kg of solid per day (low feeding rate)
Number of subjects: 48
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing feeding frequency
Number of subjects: 48
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased milk replacer allowance
Number of subjects: 48
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (50 mg/kg of BW) mixed with MR
Number of subjects: 48
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromic oxide as the external marker
Number of subjects: 48
Study 34799113 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding frequency and feeding rate treatments
Number of subjects: 48
Study 34794236 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose ACT-1004-1239 (30-200 mg o.d. in humans; 1-100 mg/kg b.i.d. in mice)
Number of subjects: 0
Study 34794236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33780099 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease management mode (CDMM)
Number of subjects: 300
Study 33780099 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 300
Study 33126931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving in-service training provided by nurses, work process organisation, and additional clinic-specific solutions in six clinics.
Number of subjects: 0
Study 33126931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive initial and subsequent in-service training provided by a physician in two clinics.
Number of subjects: 0
Study 34036820 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferenced yoga sessions
Number of subjects: 7
Study 34036820 — intervention group
Group type: COMPARATOR
Intervention: In-person yoga sessions
Number of subjects: 7
Study 32692216 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Dachengqi decoction combined with conventional therapy
Number of subjects: 40
Study 32692216 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study 34271307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 72
Study 33087178 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session online cognitive behavioral therapy (CBT) program
Number of subjects: 120
Study 33087178 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy (active control)
Number of subjects: 120
Study 33601921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4204
Study 33601921 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 4204
Study 33601921 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4204
Study 33601921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, Enoxaparin, Warfarin
Number of subjects: 4204
Study 33001334 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach encouraging MOP use (mailed letter, secure email message, automated telephone call)
Number of subjects: 63012
Study 33001334 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 63012
Study 33758499 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (90 mg ticagrelor tablets) under fasting conditions
Number of subjects: 80
Study 33758499 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (90 mg ticagrelor tablets) under fed conditions
Number of subjects: 80
Study 33758499 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (90 mg ticagrelor tablets) under fasting conditions
Number of subjects: 80
Study 33758499 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (90 mg ticagrelor tablets) under fed conditions
Number of subjects: 80
Study 33758499 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference drugs
Number of subjects: 80
Study 32876408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 32876408 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study 35385076 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36459768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib plus everolimus
Number of subjects: 399
Study 36459768 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 399
Study 36459768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorolanib
Number of subjects: 399
Study 33586526 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT point
Number of subjects: 66
Study 33586526 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWT line
Number of subjects: 66
Study 33586526 — intervention group
Group type: COMPARATOR
Intervention: ESWT placebo
Number of subjects: 66
Study 33826785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid 250 mg twice daily for three months
Number of subjects: 60
Study 33826785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid combined with topical hydroquinone 4% cream
Number of subjects: 60
Study 33826785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid combined with two sessions of 1064 nm low-fluence Q-switched Nd:YAG laser
Number of subjects: 60
Study 33568137 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with pirimiphos‐methyl (Actellic®300 CS)
Number of subjects: 1536
Study 35195481 — intervention group
Group type: EXPERIMENTAL
Intervention: Community support workers (CSWs) providing HIV health education, personal counseling, and social support for HIV patients.
Number of subjects: 1799
Study 35195481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1799
Study 34214305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment (100% O2 at 2.4 ATA for 3 × 30 min with intervals of 2 × 5 min for inhaling fresh air, once a day for 5 days)
Number of subjects: 32
Study 34214305 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoxia normobaric - NONB, 20% O2 at 1 ATA for 90 min)
Number of subjects: 32
Study 32033908 — intervention group
Group type: EXPERIMENTAL
Intervention: Palucorcel (3.0 × 10^5 cells in 50 μl) administered via subretinal injection
Number of subjects: 21
Study 32033908 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye (control)
Number of subjects: 21
Study 32876714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal block with ropivacaine 7.5 mg/ml
Number of subjects: 41
Study 32876714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 41
Study 32251064 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for estimating randomized natural direct effect (rNDE) and randomized natural indirect effect (rNIE) using regression methods.
Number of subjects: 0
Study 32251064 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear model for the conditional mean of the mediator given treatment and baseline confounders.
Number of subjects: 0
Study 32251064 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear model for the conditional mean of the outcome given treatment, mediator, and confounders.
Number of subjects: 0
Study 32251064 — intervention group
Group type: EXPERIMENTAL
Intervention: Education as a treatment variable.
Number of subjects: 0
Study 34321432 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilization (IM)
Number of subjects: 2027
Study 34321432 — intervention group
Group type: COMPARATOR
Intervention: Bed rest (BR) for 2 hours
Number of subjects: 2027
Study 33438372 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine EtG dipstick at threshold of 1000 ng/mL
Number of subjects: 12
Study 33438372 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine EtG dipstick at threshold of 1500 ng/mL
Number of subjects: 12
Study 33438372 — intervention group
Group type: COMPARATOR
Intervention: Mass spectrometry (gold standard)
Number of subjects: 12
Study 36227235 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point facial RPE scale (FCR5)
Number of subjects: 49
Study 36227235 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-point facial RPE scale (FCR10)
Number of subjects: 49
Study 36227235 — intervention group
Group type: COMPARATOR
Intervention: CR10 (Borg's category‐ratio 10‐point scale)
Number of subjects: 49
Study 36227235 — intervention group
Group type: EXPERIMENTAL
Intervention: FCR10
Number of subjects: 49
Study 33967056 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk Walking (BW)
Number of subjects: 70
Study 33967056 — intervention group
Group type: COMPARATOR
Intervention: Active Control (CON)
Number of subjects: 70
Study 33036701 — intervention group
Group type: EXPERIMENTAL
Intervention: MI plus ω‐3 (800 mg docosahexaenoic acid and 225 mg eicosapentaenoic acid/day)
Number of subjects: 1445
Study 33036701 — intervention group
Group type: EXPERIMENTAL
Intervention: MI alone
Number of subjects: 1445
Study 33036701 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation alone
Number of subjects: 1445
Study 33036701 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 1445
Study 33141278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholangioscopy-guided mapping biopsy (CMB)
Number of subjects: 28
Study 33141278 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided mapping biopsy (FMB)
Number of subjects: 28
Study 32374900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-eat vegetable salads
Number of subjects: 0
Study 34961699 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection (4 mg/0.1 ml) into the upper eyelid
Number of subjects: 32
Study 34961699 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eyelid not injected)
Number of subjects: 32
Study 34961699 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injection
Number of subjects: 32
Study 33546963 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine-based rigid lens disinfecting solution
Number of subjects: 76
Study 33546963 — intervention group
Group type: COMPARATOR
Intervention: Cleaning routines with and without daily and/or weekly cleaners
Number of subjects: 76
Study 32388538 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg oral dose)
Number of subjects: 0
Study 32388538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34644189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0
Study 34644189 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0
Study 34749549 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional high-intensity interval training (F-HIIT)
Number of subjects: 49
Study 34749549 — intervention group
Group type: COMPARATOR
Intervention: Combined training (CT)
Number of subjects: 49
Study 34237979 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (Foley1m+IUD)
Number of subjects: 96
Study 34237979 — intervention group
Group type: COMPARATOR
Intervention: Group A (IUD)
Number of subjects: 96
Study 34237979 — intervention group
Group type: COMPARATOR
Intervention: Group B (Foley1w+IUD)
Number of subjects: 96
Study 34237979 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 96
Study 32573956 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-303 8-18 mg
Number of subjects: 50
Study 32573956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50